Results 191 to 200 of about 438,052 (300)

Second primary cancers following hematologic malignancies: Epidemiology, pathobiology and clinical management. [PDF]

Hum Vaccin Immunother
Pan Y, Yang H, Shao J, Qiang X, Wang Q.
europepmc   +1 more source

Mesenchymal Stem Cells From a Klinefelter Syndrome Patient: Functional Characterization and Therapeutic Implications

Andrology, EarlyView.
ABSTRACT Background Cell therapy, particularly those utilizing mesenchymal stem/stromal cells (MSCs), is gaining traction as a therapeutic option for regenerative treatment in patients with limited therapeutic options. Although the safety of MSC‐based interventions is well established, uncertainties remain regarding how genetic abnormalities and ...
Marzena Zychowicz, Wioletta Lech, Anna Figiel‐Dabrowska, Marta Kot, Magdalena Murzyn, Natalia Malawska, Barbara Pienkowska‐Grela, Zuzanna Sandowska‐Markiewicz, Iwona Ziolkowska‐Suchanek, Agnieszka Zimna, Tomasz Oldak, Natalia Rozwadowska, Anna Sarnowska   +12 more
wiley   +1 more source

Dysbiosis-Mediated Regulation of Stem Cells the First Hit for Cancer Generation. [PDF]

Int J Mol Sci
Gargiulo-Isacco C, Pham VH, Nguyen KCD, Tran TC, Aityan SK, Del Prete R, Jirillo E, Santacroce L.   +7 more
europepmc   +1 more source

A critical appraisal of the safety of bedinvetmab (Beransa), a canine antinerve growth factor monoclonal antibody

Australian Veterinary Journal, EarlyView.
Clinical scenario Canine osteoarthritis (OA) is a degenerative joint disease and is one of the most common chronic conditions in dogs and other species. The management of OA remains a longstanding focus in veterinary medicine. Traditionally, nonsteroidal anti‐inflammatory drugs (NSAIDs) have been the first‐line treatment option for canine OA. Recently,
X Yang, P Macarthur
wiley   +1 more source

Mast cells in the bone marrow microenvironment. [PDF]

Front Immunol
Ribatti D.
europepmc   +1 more source

Immune‐related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors

British Journal of Haematology, EarlyView.
Summary Immune checkpoint inhibitors (ICIs) have shown to be effective in the treatment of Hodgkin lymphoma (HL). ICI treatment is associated with the occurrence of a series of immune‐related adverse events (irAEs). We conducted an ambispective observational study on 96 patients with relapsed/refractory HL treated with ICIs to determine the incidence ...
Lisa Argnani, Vittorio Stefoni, Beatrice Casadei, Carla Pelusi, Valentina Lo Preiato, Uberto Pagotto, Anna Buganè, Cinzia Pellegrini, Alessandro Broccoli, Pier Luigi Zinzani   +9 more
wiley   +1 more source

Establishment and Characterisation of Two Canine Prostate Cancer Cell Lines with Stem Cell Marker Expression. [PDF]

Animals (Basel)
Story MM, Stringer BW, Straw R, Palmieri C.   +3 more
europepmc   +1 more source

Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants

British Journal of Haematology, EarlyView.
Summary Constitutional pathogenic variants in DDX41 predispose to myelodysplasia and acute myeloid leukaemia. Acquisition of subsequent somatic hits in the second allele is frequent, with notable recurrent variants at key hotspots. Sequencing of Deoxyribonucleic acid from blood/marrow of 239 patients with suspected/confirmed haematological malignancies
Andrew George, Elisabeth Rolf, Monika Domeradzka, Sara Ribeiro, Brittany Mills, April Hallett, Suzanne Macmahon, Paula Proszek, Ridwan Shaikh, Lina Yuan, Michael Hubank, Mikel Valganon Petrizan, Terri P. McVeigh, Jamshid S. Khorashad   +13 more
wiley   +1 more source

Therapeutic effects of cold plasma-activated water on MCF7 breast cancer tumors in a mouse model. [PDF]

BMC Pharmacol Toxicol
Abd El-Reda G, Mahmoud MAM, Ali FAZ, Abdel-Maksoud FM, Zahran AM, El-Hossary FM.   +5 more
europepmc   +1 more source

Serum free light chain concentration and ratio‐based criterion for myeloma‐defining event, in its current version, is untenable

British Journal of Haematology, EarlyView.
Summary Clinical decision‐making based on myeloma‐defining event criteria using thresholds for involved serum free light chain level of 10 mg/dL and ratio of involved to uninvolved light chain of >100 is a poor indicator for the risk of progression to multiple myeloma.
Gurmukh Singh
wiley   +1 more source